-
Je něco špatně v tomto záznamu ?
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
K. Taskén, S. F Haj Mohammad, GL. Fagereng, R. Sørum Falk, Å. Helland, S. Barjesteh van Waalwijk van Doorn-Khosrovani, K. Steen Carlsson, B. Ryll, K. Jalkanen, A. Edsjö, HG. Russnes, U. Lassen, E. Hallersjö Hult, I. Lugowska, JY. Blay, L....
Jazyk angličtina Země Švédsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2024
PubMed Central
od 2024
Medline Complete (EBSCOhost)
od 1998-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1987
- MeSH
- Evropská unie MeSH
- individualizovaná medicína * metody MeSH
- klinické zkoušky jako téma organizace a řízení MeSH
- lidé MeSH
- nádory * terapie MeSH
- přehodnocení terapeutických indikací léčivého přípravku MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. PATIENTS AND METHODS: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. RESULTS: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. CONCLUSION: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. CONCLUSION: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
Centre Léon Bérard Lyon France
Clinical Trial Unit Comprehensive Cancer Centre Helsinki University Hospital Helsinki Finland
CZ Health Insurance Tilburg The Netherlands
Department of Clinical Genetics Pathology and Molecular Diagnostics Region Skåne Malmö Sweden
Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam The Netherlands
Department of Medical Oncology Leiden University Medical Centre Leiden The Netherlands
Department of Oncology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
Department of Oncology Sahlgrenska University Hospital Gothenburg Sweden
Department of Pathology Oslo University Hospital Oslo Norway
Division of Cancer Medicine Oslo University Hospital Oslo Norway
Hematology Oncology Clinic at Tartu University Hospital Tartu Estonia
Instituto Português de Oncologia do Porto FG Porto Portugal
Maria Sklodowska Curie Institute of Oncology Warsaw Poland
Oslo Centre for Biostatistics and Epidemiology Oslo University Hospital Oslo Norway
Stockholm School of Economics Institute for Research Stockholm Sweden
Swedish Institute for Health Economics Lund Sweden
Trinity St James Cancer Institute Trinity College Dublin Ireland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013880
- 003
- CZ-PrNML
- 005
- 20240905133948.0
- 007
- ta
- 008
- 240725e20240523sw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2340/1651-226X.2024.34791 $2 doi
- 035 __
- $a (PubMed)38779910
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Taskén, Kjetil $u Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. kjetil.tasken@medisin.uio.no
- 245 10
- $a PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe / $c K. Taskén, S. F Haj Mohammad, GL. Fagereng, R. Sørum Falk, Å. Helland, S. Barjesteh van Waalwijk van Doorn-Khosrovani, K. Steen Carlsson, B. Ryll, K. Jalkanen, A. Edsjö, HG. Russnes, U. Lassen, E. Hallersjö Hult, I. Lugowska, JY. Blay, L. Verlingue, E. Abel, MA. Lowery, MG. Krebs, K. Staal Rohrberg, K. Ojamaa, J. Oliveira, HMW. Verheul, EE. Voest, H. Gelderblom, PRIME-ROSE Consortium and the PCM4EU Consortium
- 520 9_
- $a BACKGROUND: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. PATIENTS AND METHODS: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. RESULTS: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. CONCLUSION: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. CONCLUSION: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a individualizovaná medicína $x metody $7 D057285
- 650 12
- $a nádory $x terapie $7 D009369
- 650 _2
- $a Evropská unie $7 D005062
- 650 _2
- $a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
- 650 _2
- $a klinické zkoušky jako téma $x organizace a řízení $7 D002986
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a F Haj Mohammad, Soemeya $u Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. s.f.haj_mohammad@lumc.nl
- 700 1_
- $a Fagereng, Gro Live $u Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. gfageren@ous-hf.no
- 700 1_
- $a Sørum Falk, Ragnhild $u Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. rs@ous-hf.no
- 700 1_
- $a Helland, Åslaug $u Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. aslaug.helland@medisin.uio.no
- 700 1_
- $a Barjesteh van Waalwijk van Doorn-Khosrovani, Sahar $u Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands; CZ Health Insurance, Tilburg, The Netherlands. sahar.van.waalwijk@cz.nl
- 700 1_
- $a Steen Carlsson, Katarina $u Swedish Institute for Health Economics, Lund, Sweden. katarina.steen_carlsson@ihe.se
- 700 1_
- $a Ryll, Bettina $u Stockholm School of Economics Institute for Research, Stockholm, Sweden. Bettina.Ryll@hhs.se
- 700 1_
- $a Jalkanen, Katriina $u Clinical Trial Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland. katriina.jalkanen@hus.fi
- 700 1_
- $a Edsjö, Anders $u Department of Clinical Genetics, Pathology and Molecular Diagnostics, Region Skåne, Malmö, Sweden. anders.edsjo@skane.se
- 700 1_
- $a Russnes, Hege G $u Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway. h.e.g.russnes@medisin.uio.no
- 700 1_
- $a Lassen, Ulrik $u Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ulrik.lassen@regionh.dk
- 700 1_
- $a Hallersjö Hult, Ebba $u Stockholm School of Economics Institute for Research, Stockholm, Sweden. ebba.hallersjo.hult@hhs.se
- 700 1_
- $a Lugowska, Iwona $u Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland. Iwona.Lugowska@nio.gov.pl
- 700 1_
- $a Blay, Jean-Yves $u Centre Léon Bérard, Lyon, France. jean-yves.blay@lyon.unicancer.fr
- 700 1_
- $a Verlingue, Loic $u Centre Léon Bérard, Lyon, France. Loic.VERLINGUE@lyon.unicancer.fr
- 700 1_
- $a Abel, Edvard $u Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. edvard.abel@vgregion.se
- 700 1_
- $a Lowery, Maeve A $u Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. MLOWERY@tcd.ie
- 700 1_
- $a Krebs, Matthew G $u Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@nhs.net
- 700 1_
- $a Staal Rohrberg, Kristoffer $u Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. kristoffer.staal.rohrberg@regionh.dk
- 700 1_
- $a Ojamaa, Kristiina $u Hematology-Oncology Clinic at Tartu University Hospital, Tartu, Estonia. Kristiina.Ojamaa@kliinikum.ee
- 700 1_
- $a Oliveira, Julio $u Instituto Português de Oncologia do Porto FG, Porto, Portugal. julio.oliveira@ipoporto.min-saude.pt
- 700 1_
- $a Verheul, Henk M W $u Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. h.verheul@erasmusmc.nl
- 700 1_
- $a Voest, Emile E $u Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl
- 700 1_
- $a Gelderblom, Hans $u Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. a.j.gelderblom@lumc.nl
- 710 2_
- $a PRIME-ROSE Consortium and the PCM4EU Consortium
- 773 0_
- $w MED00009028 $t Acta oncologica $x 1651-226X $g Roč. 63 (20240523), s. 385-391
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38779910 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133942 $b ABA008
- 999 __
- $a ok $b bmc $g 2143598 $s 1225746
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 63 $c - $d 385-391 $e 20240523 $i 1651-226X $m Acta oncologica $n Acta Oncol $x MED00009028
- LZP __
- $a Pubmed-20240725
